Walker S, Cox E, Rothwell B, et al. - This economic assessment was undertaken utilizing UK data for 1,202 patients from the Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease 2 trial, to evaluate the following management strategies in terms of cost-effectiveness when employed in patients presenting with chest pain and suspected coronary heart disease: (1) cardiovascular magnetic resonance (CMR); (2) myocardial perfusion scintigraphy (MPS); and (3) UK National Institute for Health and Care Excellence (NICE) guideline-guided care. Quality-adjusted life-years (QALYs) expressed health outcomes, and expenses reflected UK pound sterling in 2016–2017. The highest QALY gain overall was reported for CMR. CMR incurred comparable costs. Overall, CMR-guided care was identified to be cost-effective overall and across all pretest likelihood subgroups, vs MPS and NICE guidelines.